Anxiety is one of the more common reasons people look into ibogaine, and it is also one of the least directly researched. No published study has set out to treat anxiety with ibogaine as its primary aim. What exists is a single cohort in which anxiety was measured properly as a secondary outcome, and the result was large enough to be worth examining closely rather than either dismissing or overstating.

This entry sets out that one dataset, explains the conditions under which it was collected, and separates what the finding supports from what it does not. The distinction matters because an outcome measured as a secondary endpoint in an uncontrolled study is a different kind of evidence from a treatment effect established in a trial designed to test it.

The state of the evidence

There is no trial of ibogaine for generalised anxiety disorder, panic disorder, social anxiety or any other specific anxiety diagnosis. There is one prospective observational study in which standardised anxiety scores were recorded before and after treatment in a defined group, and a preprint following the same group for a year. Everything else is inference from adjacent findings, mostly in rodents or in cell preparations.

The broader picture is the usual one in this field. A 2026 review of three decades of human ibogaine research found that most positive efficacy data come from uncontrolled, open-label or retrospective studies, many conducted outside clinical settings and at high risk of bias, and noted that observational data suggest ibogaine may ease symptoms in opioid use disorder, post-traumatic stress disorder and polysubstance dependence [3]. Anxiety appears in that literature as something measured alongside those conditions rather than as a target.

Where the numbers come from

The dataset is the Stanford MISTIC cohort: 30 male US Special Operations Forces veterans, mean age 44.9, with a history of repeated blast and combat exposure and a mean of 38.6 lifetime traumatic brain injuries. At baseline, structured diagnostic interview identified an anxiety disorder in 14 of the 30, post-traumatic stress disorder in 23, major depression in 15 and alcohol use disorder in 15 [1].

The design was prospective, observational, open label and single arm, with no control group, no blinding and no power calculation. Participants arranged their own treatment at a clinic in Mexico, funded by a veterans' nonprofit, and were assessed separately at Stanford two to three days before treatment, four to five days after, and at one month. Stanford had no role in the dosing [1].

One element of the protocol has a direct bearing on the anxiety numbers. Before treatment, participants stopped all psychiatric medications, along with benzodiazepines, stimulants, serotonergic drugs, beta blockers, calcium channel blockers, corticosteroids and CYP2D6 inhibitors [1]. Benzodiazepines and antidepressants are both used for anxiety. Withdrawing them shortly before a baseline assessment can raise the baseline score, and a raised baseline makes any subsequent fall look larger. That is not a criticism of the study, which had good pharmacological reasons for the washout, but it is a factor in reading the magnitude of the change.

The cohort itself also limits what the anxiety finding can be generalised to. These were men who had already decided to seek ibogaine treatment abroad, who had the means and the support of a nonprofit to do so, and whose anxiety sat inside a dense cluster of other conditions: post-traumatic stress in 23 of 30, depression in 15, alcohol use disorder in 15, and a mean of 38.6 lifetime head injuries [1]. Anxiety in that context is not the same clinical entity as anxiety in someone without a trauma history or an injury burden, and a change in one population says little about the other.

What was actually measured

Anxiety was assessed with a standard clinician-rated scale. Scores fell from 20.8 at baseline to 3.6 immediately after treatment and 3.9 at one month [1]. Alongside it, clinician-rated post-traumatic stress scores fell from 31.7 to 3.9 and then 4.8, with effect sizes of 2.30 and 2.54, and depression scores fell from 25.6 to 2.8 and then 3.8, with effect sizes of 2.65 and 2.80. Suicidal ideation, present in 47 percent at baseline, was absent immediately after treatment and present in 7 percent at one month. Remission rates of 83 to 86 percent were reported across the psychiatric measures.

A reduction from roughly 21 to under 4 on that kind of scale is the difference between marked symptoms and essentially none. Effect sizes above 2 are substantially larger than established anxiety treatments produce in controlled trials. That is precisely why the design matters: uncontrolled studies systematically overstate effects, and the larger the reported effect in an uncontrolled study, the more weight the design limitations have to carry.

A companion qualitative analysis of the same participants gives some texture to what changed. Four themes emerged from their written accounts: re-encountering and re-appraising traumatic memories, often with forgiveness and acceptance; an observer-like or dissolved sense of self; emotional resolution; and bodily sensations interpreted as healing [4]. Several of those map onto mechanisms by which anxiety plausibly eases, particularly a change in the relationship to threatening memories. They are participants' own descriptions, collected on average 13 days after treatment, and are not evidence of mechanism.

If something here speaks to your situation, the next step is a five-minute provider match profile. We read it personally, take your case to vetted providers, and come back with the ones who say yes — or tell you honestly if ibogaine is not the answer.

Find a provider

Whether it held

A follow-up of the same cohort reports that improvements persisted. Twenty-five of the 30 completed assessment at 12 months, with effect sizes at or above 2.18, and estimated probabilities of sustained remission of 84 percent for post-traumatic stress, 66 percent for depression and 61 percent for anxiety [2].

Anxiety had the lowest sustained remission estimate of the three, which is worth noting rather than glossing. It suggests that whatever the treatment did for anxiety in this group was somewhat less durable than its effect on post-traumatic stress. That report is a preprint and has not completed peer review, with a journal decision to revise recorded in February 2026 [2], so the figures should be treated as provisional.

Why anxiety has not been studied directly

Several reasons converge. The research effort has been concentrated on opioid use disorder, where the observed effect is most distinctive and the unmet need most acute. Ibogaine's cardiac profile makes any trial expensive and tightly constrained, so the first indications pursued tend to be severe conditions with poor existing options. Anxiety, by contrast, has multiple established treatments with well-characterised safety, which raises the bar for testing a drug that requires cardiac monitoring.

There is also a practical obstacle to trial design. A full ibogaine dose is unmistakable to the person taking it, so blinding is difficult, and anxiety outcomes depend heavily on self-report and clinician interview. In an unblinded study of an anxiety treatment, expectancy effects are hard to distinguish from drug effects, which is a general problem in this field and an acute one for this particular outcome.

What a direct study would require is not mysterious. It would need an anxiety diagnosis as the entry criterion rather than an incidental finding, a comparison group assessed on the same schedule, a stable medication position at baseline rather than a recent washout, and an endpoint less dependent on the participant knowing what they received. It would also need cardiac screening and monitoring sufficient for a population not selected for cardiac fitness. None of that is impossible, and none of it has been done.

In the meantime, the honest description of the position is that anxiety improved markedly in one group of people who received ibogaine for other reasons, and that no one has tested whether ibogaine treats anxiety. Those two statements are compatible, and the second is the one that bears on a decision.

What might account for it

Any mechanistic account here is provisional, because the mechanism of ibogaine's main effects is itself unresolved. The 2019 review that catalogues its receptor binding states that the mechanism behind its effect on drug-seeking behaviour remains unknown, and notes that the receptor interactions documented do not appear to account for the long-lasting effects seen in rodents [5].

Two threads are at least relevant. In rats, both ibogaine and noribogaine raised extracellular serotonin in the nucleus accumbens and inhibited serotonin uptake, with noribogaine roughly ten times more potent than ibogaine as an indirect serotonin agonist. Both also raised the stress hormones corticosterone and prolactin [6]. Serotonergic action is a familiar route to anxiety reduction, though the hormone finding points in the opposite direction and the data are from rodents.

Separately, cell-based work found noribogaine to be a kappa-opioid agonist biased toward G protein signalling over beta-arrestin recruitment, a profile the authors suggested might explain why it lacks the dysphoric effects usually associated with kappa activation [7]. That is in vitro and has no human confirmation. Neither thread amounts to an explanation of the anxiety findings; they are the material from which hypotheses would be built.

The risk side of the question

For anxiety specifically, the risk calculation differs from the one that applies in opioid dependence, and it differs in an unfavourable direction. The cardiac effect is the same regardless of why someone takes the drug. In a closely screened Dutch series of 14 patients, maximum QT prolongation averaged 95 milliseconds, 7 of 14 exceeded 500 milliseconds, and in 6 of 14 the abnormality persisted beyond 24 hours. All 14 experienced severe transient ataxia and were unable to walk unaided [8].

There is a further consideration specific to anxiety. The treatment itself is a prolonged and intense psychoactive experience lasting most of a day, with vivid internal imagery and, in the Dutch series, an inability to walk unaided throughout [8]. For a person whose presenting problem is anxiety, that is a demanding experience to enter, and the qualitative accounts from the veteran cohort describe re-encountering traumatic material as a central feature of it [4]. Whether that is therapeutic or destabilising is not something the existing data can predict for an individual.

Someone with opioid dependence is weighing that risk against a condition with high mortality. Someone with anxiety is weighing it against treatments that do not prolong the QT interval and do not require continuous cardiac monitoring. That comparison is part of an honest account of the question, and it does not depend on any view about whether the anxiety findings will hold up.

Frequently asked questions

Has ibogaine been tested for anxiety?

Not as a primary aim. Anxiety was measured as a secondary outcome in one prospective observational cohort of 30 veterans, where scores fell from 20.8 to 3.9 at one month [1]. There is no controlled trial in any anxiety diagnosis.

Why were the reductions so large?

Partly unknown, and partly explicable by design. The study had no control group and no blinding, participants had stopped all psychiatric medication including benzodiazepines before the baseline assessment [1], and uncontrolled designs tend to overstate effects [3].

Did the anxiety improvement last?

In a preprint following the same cohort, sustained remission for anxiety at 12 months was estimated at 61 percent, the lowest of the three psychiatric measures reported [2]. That report has not completed peer review.

Would anxiety alone be a reason to consider ibogaine?

Nothing in the published evidence supports that. The cohort studied had severe post-traumatic stress, depression and a heavy brain injury history alongside anxiety [1], and the cardiac risk applies regardless of indication [8].

Safety. Ibogaine prolongs the heart's QT interval and can trigger dangerous arrhythmias. Treatment requires an EKG and bloodwork before dosing, continuous cardiac monitoring during, and medically trained staff present. Ibogaine is not safe to take unsupervised.
Disclaimer: This entry is general information, not medical advice.

References

  1. Cherian KN, Keynan JN, Anker L, et al. 2024, Nat Med 30(2):373-381. doi:10.1038/s41591-023-02705-w. PMID 38182784. PMC10878970. ClinicalTrials.gov NCT04313712. europepmc.org/article/PMC/PMC10878970
  2. Rolle C, Williams N, Faerman A, Lissemore J, et al. 2025, Research Square preprint. doi:10.21203/rs.3.rs-6909189/v1. Not peer reviewed (journal decision "revise", 5 Feb 2026). researchsquare.com/article/rs-6909189/v1
  3. Kervadec E, Bezo A, Serreau R, et al. 2026, J Clin Psychopharmacol. doi:10.1097/jcp.0000000000002197. PMID 42228481. doi.org/10.1097/jcp.0000000000002197
  4. Olash C, Buchanan DM, Brown R, et al. 2026, npj Ment Health Res 5. doi:10.1038/s44184-026-00185-7. PMID 41620509. doi.org/10.1038/s44184-026-00185-7
  5. Marton S, Gonzalez B, Rodriguez-Bottero S, et al. 2019, Front Pharmacol 10:193. frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2019.00193/full
  6. Baumann MH, Rothman RB, Pablo JP, Mash DC. 2001, J Pharmacol Exp Ther 297(2):531-539. PMID 11303040. europepmc.org/article/MED/11303040
  7. Maillet EL, Milon N, Heghinian MD, Fishback J, Schurer SC, Garamszegi N, Mash DC. 2015, Neuropharmacology 99:675-688. doi:10.1016/j.neuropharm.2015.08.032. PMID 26302653. doi.org/10.1016/j.neuropharm.2015.08.032
  8. Knuijver T, Schellekens A, Belgers M, et al. 2022, Addiction 117(1). doi:10.1111/add.15448. PMC9292417. europepmc.org/article/PMC/PMC9292417